Program
GZR4
A development code. Also written as “GZR4 Injection”.
Its studies are mostly in Diabetes Mellitus · Diabetes Mellitus, Type 2, led by Gan & Lee Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gan & Lee Pharmaceuticals | 95 open or running | phase 3since Jan 5, 2025 | Jan 2, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 2, 2024First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT06202079 · 179 enrolled · China
- Aug 5, 20244 phase 1 studiesNCT06548815, NCT06553248, NCT06547502 and 1 more
- Jan 5, 20252 phase 3 studies in Diabetes MellitusNCT06767761, NCT06767735
- Sep 3, 2025Phase 3 study in Diabetes MellitusNCT07165223 · 300 planned · China
- Sep 18, 2025Phase 1 study in Diabetes MellitusNCT07193147 · 36 enrolled · China
Ahead
- Nov 10, 2026Primary completion: phase 3 study in Diabetes MellitusNCT07165223
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07193147Diabetes Mellitus · China | 1 | Active, not recruiting | Jul 14, 2026 | 36 |
| NCT07165223Diabetes Mellitus · China | 3 | Recruiting | Nov 10, 2026 | 300 |
| NCT06767761Diabetes Mellitus · China | 3 | Active, not recruiting | Mar 19, 2026 | 580 |
| NCT06767735Diabetes Mellitus · China | 3 | Active, not recruiting | Aug 1, 2026 | 580 |
| NCT06548906Healthy Subjects · China | 1 | Recruiting | Aug 31, 2024 | 24 |
| NCT06553248Diabetes Mellitus · China | 1 | Completed | Nov 1, 2023 | 36 |
| NCT06547502Diabetes Mellitus · China | 1 | Completed | Aug 20, 2024 | 16 |
| NCT06548815Diabetes Mellitus · China | 1 | Completed | Mar 24, 2023 | 43 |
| NCT06202079Diabetes Mellitus, Type 2 · China | 2 | Completed | Jul 13, 2024 | 179 |
How it is read
Names in the registry
- “GZR4”, 7 entries
- “GZR4 Injection”, 2 entries
Codes read as this program: GZR4.
Conditions, from the studies’ own filings
- Diabetes Mellitus, 7 studies
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.